SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Gilbert Ethel)
 

Sökning: WFRF:(Gilbert Ethel) > Lung cancer followi...

  • Travis, Lois BNational Cancer Institute, USA (författare)

Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease

  • Artikel/kapitelEngelska2002

Förlag, utgivningsår, omfång ...

  • Oxford University Press (OUP),2002
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-222094
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-222094URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:18073956URI
  • https://doi.org/10.1093/jnci/94.3.182DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BACKGROUND: Lung cancer is a frequent cause of death in patients cured of Hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described. We quantified the risk of treatment-associated lung cancer, taking into account tobacco use.METHODS: Within a population-based cohort of 19 046 Hodgkin's disease patients (diagnosed from 1965 through 1994), a case-control study of lung cancer was conducted. The cumulative amount of cytotoxic drugs, the radiation dose to the specific location in the lung where cancer developed, and tobacco use were compared for 222 patients who developed lung cancer and for 444 matched control patients. All statistical tests were two-sided.RESULTS: Treatment with alkylating agents without radiotherapy was associated with increased lung cancer risk (relative risk [RR] = 4.2; 95% confidence interval [CI] = 2.1 to 8.8), as was radiation dose of 5 Gy or more without alkylating agents (RR = 5.9; 95% CI = 2.7 to 13.5). Risk increased with both increasing number of cycles of alkylating agents and increasing radiation dose (P for trend <.001). Among patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), risk increased with cumulative amounts of mechlorethamine and procarbazine (P<.001) when evaluated separately. Statistically significantly elevated risks of lung cancer were apparent within 1-4 years after treatment with alkylating agents, whereas excess risk after radiotherapy began 5 years after treatment and persisted for more than 20 years. Risk after treatment with alkylating agents and radiotherapy together was as expected if individual excess risks were summed. Tobacco use increased lung cancer risk more than 20-fold; risks from smoking appeared to multiply risks from treatment.CONCLUSIONS: Past treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion. The precise risk estimates, however, should be interpreted cautiously, given the possible residual and enhancing effects of tobacco.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gospodarowicz, MaryCanada (författare)
  • Curtis, Rochelle ENational Cancer Institute, USA (författare)
  • Clarke, E AileenToronto (författare)
  • Andersson, MichaelDenmark (författare)
  • Glimelius, BengtKarolinska Institutet,Uppsala universitet,Enheten för onkologi(Swepub:uu)bengglim (författare)
  • Joensuu, TimoFinland (författare)
  • Lynch, Charles FIowa (författare)
  • van Leeuwen, Flora EThe Netherlands (författare)
  • Holowaty, EricToronto (författare)
  • Storm, HansDenmark (författare)
  • Glimelius, IngridUppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap,Karolinska Institutet(Swepub:uu)inggl846 (författare)
  • Pukkala, EeroFinland (författare)
  • Stovall, MarilynHouston (författare)
  • Fraumeni, Joseph F,JrNational Cancer Institute, USA (författare)
  • Boice, John D,JrUSA (författare)
  • Gilbert, EthelNational Cancer Institute, USA (författare)
  • National Cancer Institute, USACanada (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of the National Cancer Institute: Oxford University Press (OUP)94:3, s. 182-1920027-88741460-2105

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy